2024 saw our clients raise nearly US$2 billion in what turned out to be a busy year! As we head into 2025, we hope to see the funding translate into results in the clinic, with many more financings in the pipeline. Seed Disco Pharmaceuticals (Germany) launched with a €20 million (US$21 million) seed financing to […]
Ottimo Pharma, a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, on Thursday announced the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumour indications, in both IV and […]
Optimum spoke to some of Europe’s leading life science VCs to discover what they are looking for from potential investee companies and their top predictions for the next 12 months. Participants from major investment firms shared their insights on the funding environment for 2025, how to secure funding in a difficult market, and explain why […]
VCs favouring new investments over existing portfolio and have money to deploy M&A expected to be strong Top investor requirements – Team, Science and Differentiation London, UK, 11 December 2024: Optimum Strategic Communications (‘Optimum’), the international strategic life sciences communications firm, today announces the results of its Optimum European Life Sciences Investor Survey 2025: […]
